The Pharmacology of Bisphosphonates: New Advances

Dear Colleagues,

Bisphosphonates (BPs) were first discovered in 1894 by the pharmacist Theodor Salzer. At that time, they were mainly used in industrial processes (in the textile, fertilizer, and oil industries) as corrosion inhibitors or as complexing agents. Bisphosphonates (BPs) are a class of compounds which are receiving growing interest in the pharmaceutical industry. Their therapeutic properties in bone-related disorders (e.g., osteoporosis, Paget′s disease, or bone metastases) makes them the focus of several research studies as well as the main component of numerous pharmaceutical formulations. Their antiresorptive action is related to their high affinity for hydroxyapatite, the main inorganic substituent of bone. On the other hand, the phosphonate groups on their backbone make them excellent ligands for metal ions. The combination of these properties finds potential application in the utilization of such systems as controlled drug release systems (CRSs). Thus, bisphosphonates are currently the target of intensive research, from basic pre-formulation studies to more advanced stages of clinical practice. In addition to such important medicinal use, they display a variety of physiologic activities, which also make them promising anti-cancer, antiprotozoal, antibacterial, and antiviral agents.

It is my great pleasure to invite experts in the field of bisphosphonates to submit manuscripts in the form of short communications, full-length papers, and reviews to this Special Issue. Potential topics include, but are not limited to, the following: innovative synthetic approaches for the preparation of bioactive bisphosphonates, the bioactivity screening of bisphosphonic acids, repurposing and newly discovered biological effects of known compounds, as well as molecular modeling and structure–activity relationship studies. All types of research are encouraged, from in silico studies, through all varieties of in vitro and in vivo research to epidemiological, prospective, and retrospective clinical studies.

I look forward to your valuable contributions.

Dr. Ewa Chmielewska
Prof. Dr. Paweł Kafarski
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.